Cargando…

Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men

Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb(mass)) and maximal oxygen uptake ([Image: see text] O(2 max)). PURPOSE: This study defined the time course of changes in Hb(mass), [Image: see text] O(2 max) as well as running time trial performance following 4 weeks of rHuEpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Durussel, Jérôme, Daskalaki, Evangelia, Anderson, Martin, Chatterji, Tushar, Wondimu, Diresibachew H., Padmanabhan, Neal, Patel, Rajan K., McClure, John D., Pitsiladis, Yannis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571963/
https://www.ncbi.nlm.nih.gov/pubmed/23418527
http://dx.doi.org/10.1371/journal.pone.0056151
_version_ 1782259245328105472
author Durussel, Jérôme
Daskalaki, Evangelia
Anderson, Martin
Chatterji, Tushar
Wondimu, Diresibachew H.
Padmanabhan, Neal
Patel, Rajan K.
McClure, John D.
Pitsiladis, Yannis P.
author_facet Durussel, Jérôme
Daskalaki, Evangelia
Anderson, Martin
Chatterji, Tushar
Wondimu, Diresibachew H.
Padmanabhan, Neal
Patel, Rajan K.
McClure, John D.
Pitsiladis, Yannis P.
author_sort Durussel, Jérôme
collection PubMed
description Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb(mass)) and maximal oxygen uptake ([Image: see text] O(2 max)). PURPOSE: This study defined the time course of changes in Hb(mass), [Image: see text] O(2 max) as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field. METHODS: 19 trained men received rHuEpo injections of 50 IU•kg(−1) body mass every two days for 4 weeks. Hb(mass) was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. [Image: see text] O(2 max) and 3,000 m time trial performance were measured pre, post administration and at the end of the study. RESULTS: Relative to baseline, running performance significantly improved by ∼6% after administration (10∶30±1∶07 min:sec vs. 11∶08±1∶15 min:sec, p<0.001) and remained significantly enhanced by ∼3% 4 weeks after administration (10∶46±1∶13 min:sec, p<0.001), while [Image: see text] O(2 max) was also significantly increased post administration (60.7±5.8 mL•min(−1)•kg(−1) vs. 56.0±6.2 mL•min(−1)•kg(−1), p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min(−1)•kg(−1), p = 0.021). Hb(mass) was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg(−1) vs. 12.7±1.2 g•kg(−1), p<0.001). The rate of decrease in Hb(mass) toward baseline values post rHuEpo was similar to that of the increase during administration (−0.53 g•kg(−1)•wk(−1), 95% confidence interval (CI) (−0.68, −0.38) vs. 0.54 g•kg(−1•)wk(−1), CI (0.46, 0.63)) but Hb(mass) was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg(−1), p<0.001). CONCLUSION: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated [Image: see text] O(2 max) and Hb(mass).
format Online
Article
Text
id pubmed-3571963
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35719632013-02-15 Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men Durussel, Jérôme Daskalaki, Evangelia Anderson, Martin Chatterji, Tushar Wondimu, Diresibachew H. Padmanabhan, Neal Patel, Rajan K. McClure, John D. Pitsiladis, Yannis P. PLoS One Research Article Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb(mass)) and maximal oxygen uptake ([Image: see text] O(2 max)). PURPOSE: This study defined the time course of changes in Hb(mass), [Image: see text] O(2 max) as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field. METHODS: 19 trained men received rHuEpo injections of 50 IU•kg(−1) body mass every two days for 4 weeks. Hb(mass) was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. [Image: see text] O(2 max) and 3,000 m time trial performance were measured pre, post administration and at the end of the study. RESULTS: Relative to baseline, running performance significantly improved by ∼6% after administration (10∶30±1∶07 min:sec vs. 11∶08±1∶15 min:sec, p<0.001) and remained significantly enhanced by ∼3% 4 weeks after administration (10∶46±1∶13 min:sec, p<0.001), while [Image: see text] O(2 max) was also significantly increased post administration (60.7±5.8 mL•min(−1)•kg(−1) vs. 56.0±6.2 mL•min(−1)•kg(−1), p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min(−1)•kg(−1), p = 0.021). Hb(mass) was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg(−1) vs. 12.7±1.2 g•kg(−1), p<0.001). The rate of decrease in Hb(mass) toward baseline values post rHuEpo was similar to that of the increase during administration (−0.53 g•kg(−1)•wk(−1), 95% confidence interval (CI) (−0.68, −0.38) vs. 0.54 g•kg(−1•)wk(−1), CI (0.46, 0.63)) but Hb(mass) was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg(−1), p<0.001). CONCLUSION: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated [Image: see text] O(2 max) and Hb(mass). Public Library of Science 2013-02-13 /pmc/articles/PMC3571963/ /pubmed/23418527 http://dx.doi.org/10.1371/journal.pone.0056151 Text en © 2013 Durussel et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Durussel, Jérôme
Daskalaki, Evangelia
Anderson, Martin
Chatterji, Tushar
Wondimu, Diresibachew H.
Padmanabhan, Neal
Patel, Rajan K.
McClure, John D.
Pitsiladis, Yannis P.
Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men
title Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men
title_full Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men
title_fullStr Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men
title_full_unstemmed Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men
title_short Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men
title_sort haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571963/
https://www.ncbi.nlm.nih.gov/pubmed/23418527
http://dx.doi.org/10.1371/journal.pone.0056151
work_keys_str_mv AT durusseljerome haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen
AT daskalakievangelia haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen
AT andersonmartin haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen
AT chatterjitushar haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen
AT wondimudiresibachewh haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen
AT padmanabhanneal haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen
AT patelrajank haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen
AT mcclurejohnd haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen
AT pitsiladisyannisp haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen